Yantai Dongcheng Pharmaceutical GroupLtd Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Yantai Dongcheng Pharmaceutical GroupLtd kazanç ve gelirin sırasıyla yıllık 45.3% ve 13.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 45.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

45.3%

Kazanç büyüme oranı

45.8%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.3%
Gelir büyüme oranı	13.1%
Gelecekteki özkaynak getirisi	7.6%
Analist kapsamı	Good
Son güncelleme	01 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet

Aug 23

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price

Jul 12

News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat

May 06

Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

May 05

Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Mar 15

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Feb 27

Kazanç ve Gelir Büyüme Tahminleri

SZSE:002675 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,906	426	N/A	760	5
12/31/2025	3,452	332	N/A	664	6
12/31/2024	3,119	264	N/A	648	6
9/30/2024	2,853	91	-167	362	N/A
6/30/2024	2,911	137	-280	247	N/A
3/31/2024	3,072	224	-340	204	N/A
12/31/2023	3,276	210	-235	277	N/A
9/30/2023	3,427	263	35	490	N/A
6/30/2023	3,603	323	199	664	N/A
3/31/2023	3,554	302	467	853	N/A
1/1/2023	3,583	307	607	997	N/A
9/30/2022	3,858	220	415	986	N/A
6/30/2022	3,851	165	292	833	N/A
3/31/2022	3,902	140	295	846	N/A
1/1/2022	3,912	152	413	944	N/A
9/30/2021	3,637	341	445	788	N/A
6/30/2021	3,599	353	702	1,023	N/A
3/31/2021	3,596	411	333	618	N/A
12/31/2020	3,419	418	310	573	N/A
9/30/2020	3,395	214	339	645	N/A
6/30/2020	3,312	196	149	443	N/A
3/31/2020	3,172	164	508	760	N/A
12/31/2019	2,993	155	446	696	N/A
9/30/2019	2,877	366	335	500	N/A
6/30/2019	2,709	347	458	577	N/A
3/31/2019	2,467	302	305	457	N/A
12/31/2018	2,333	280	372	493	N/A
9/30/2018	2,098	228	458	600	N/A
6/30/2018	1,842	212	N/A	444	N/A
3/31/2018	1,679	185	N/A	339	N/A
12/31/2017	1,596	173	N/A	209	N/A
9/30/2017	1,511	172	N/A	79	N/A
6/30/2017	1,377	149	N/A	106	N/A
3/31/2017	1,245	145	N/A	106	N/A
12/31/2016	1,158	131	N/A	196	N/A
9/30/2016	1,014	119	N/A	210	N/A
6/30/2016	903	95	N/A	109	N/A
3/31/2016	852	83	N/A	103	N/A
12/31/2015	795	90	N/A	67	N/A
9/30/2015	725	94	N/A	36	N/A
6/30/2015	724	99	N/A	40	N/A
3/31/2015	727	103	N/A	-16	N/A
12/31/2014	751	104	N/A	52	N/A
9/30/2014	786	99	N/A	2	N/A
6/30/2014	783	96	N/A	-10	N/A
3/31/2014	782	91	N/A	66	N/A
12/31/2013	775	101	N/A	-21	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 002675 'nin tahmini kazanç büyümesi (yıllık 45.3% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 002675 şirketinin kazançlarının (yıllık 45.3% ) CN pazarından (yıllık 26.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 002675 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 002675 şirketinin gelirinin (yıllık 13.1% ) CN pazarından (yıllık 13.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 002675 şirketinin gelirinin (yıllık 13.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 002675 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.6 %).

Yantai Dongcheng Pharmaceutical GroupLtd Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 14%

Price target decreased by 12% to CN¥17.80

Consensus EPS estimates fall by 36%

Recent updates

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Proposes Dividend for the Third Quarter of 2024

Third quarter 2024 earnings released: EPS: CN¥0.067 (vs CN¥0.12 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Consensus EPS estimates fall by 14%

Second quarter 2024 earnings released: EPS: CN¥0.058 (vs CN¥0.16 in 2Q 2023)

Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Price target decreased by 12% to CN¥17.80

News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat

Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

Consensus EPS estimates fall by 36%

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 15%

Now 25% undervalued after recent price drop

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Now 21% undervalued

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.20 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 2Q 2022)

High number of new and inexperienced directors

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 10 July 2023

Now 21% undervalued after recent price drop

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for 2022

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.061 (vs CN¥0.069 in 1Q 2022)

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.13 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.11 in 2Q 2021)

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 09 June 2022

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2021

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.15 in 3Q 2020)

Yantai Dingying Investment Partnership (Limited) Partnership) and Chen Xiaoyuan acquired 25% stake in Shanghai Lannacheng Biotechnology Co., Ltd. from Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) and Xu Ye.

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.18 in 2Q 2020)

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2020, Payable on 4 June 2021

Full year 2020 earnings released: EPS CN¥0.52 (vs CN¥0.19 in FY 2019)

New 90-day low: CN¥18.22

New 90-day low: CN¥18.29

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Executive Changes

New 90-day low: CN¥19.30

Investor sentiment deteriorated over the past week

New 90-day low: CN¥21.28

New 90-day high: CN¥25.90

Third quarter earnings released

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

First half earnings released

New 90-day high - CN¥24.97

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report First Half, 2020 Results on Aug 07, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin